Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales
The Ahmedabad based hospital in association with Sankalp India Foundation had established the BMT unit in 2017
Arrow is the marketing partner in US
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Our portfolio transformation over the past few years positions us well to capitalize on improving end market conditions and deliver differentiated results in the years to come
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
Eltrombopag tablets will be produced at the group’s formulation manufacturing facility at SEZ, Ahmedabad
Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
Subscribe To Our Newsletter & Stay Updated
